John Josey
Venture Partner at The Column Group
Dallas, Texas
Overview
Work Experience
Venture Partner
2020 - Current
Board Chair
2022
Honored to be working with The Column Group, Lux Capital and Nextech Invest to build a great drug-discovery organization in Cambridge, MA. Particularly delighted that Marion Dorsch, a seasoned drug-hunter, is leading the scientific effort as President & Chief Scientific Officer at Atavistik Bio, Inc.
Atavistik Bio is a biotechnology company that focuses on the discovery and development of novel therapies for metabolic diseases and cancer.
Raised $100,000,000.00 from Lux Capital, Nextech Invest and The Column Group.
President and Chief Executive Officer
2013 - 2019
President and Chief Scientific Officer
2011 - 2013
Vice President, Discovery Chemistry
1998 - 2011
Array BioPharma is a biopharmaceutical company focused on the development and commercialization of targeted small molecule drugs.
Raised $412,100,000.00 from Redmile Group.
Scientist
1995 - 1998
Amgen is a biotechnology company that develops and manufactures human therapeutics for various illnesses and diseases.
Raised $28,500,000,000.00 from Citibank and Bank of America.
Research Scientist
1991 - 1995